Better Therapeutics- Tradeable Rights - March 2021 Total Current Liabilities

The latest total current liabilities for MCADR is $13M as of September 2023. That compares with $9.3M in the prior-year period — up 38.9% year over year. Investors often review this figure alongside Better Therapeutics- Tradeable Rights - March 2021's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCADR's total current liabilities moved from $9.3M to $13M — a 38.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics- Tradeable Rights - March 2021's operating scale or balance-sheet position.

A total current liabilities figure of $13M for MCADR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MCADR's total current liabilities ($13M), review year-over-year change from $9.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.